The antiviral drugs market is anticipated to flourish at an average CAGR of 3.9% between 2023 and 2033. The market is expected to hold a market share of USD 89.68 billion by 2033, while the market is likely to reach a value of USD 61.42 billion in 2023.
| Attributes | Details |
|---|---|
| Antiviral Drugs Market CAGR (2023 to 2033) | 3.9% |
| Antiviral Drugs Market Size (2023) | USD 61.42 billion |
| Antiviral Drugs Market Size (2033) | USD 89.68 billion |
Antiviral drugs are medicines that are used especially for treating viral infections. Most antiviral drugs are used for particular viral infections, similar to antibiotics, while a broad-spectrum antiviral drug is effective against a varied range of viruses. Antiviral drugs do not kill their target pathogen. Instead, they inhibit the development of those viruses.
The global antiviral drugs market is projected to register a moderate growth rate in the pharmaceutical market and is anticipated to increase due to a rise in awareness level, an increase in the diseased population, and the introduction of new drugs with improved efficacy.
Some key patents are reaching their expiry during the forecast periods, such as Combivir, Sustiva, Tenofovir, Tamiflu, Relenza, and Telbivudine. The patent expiries of these blockbuster drugs are expected to trigger generic competition in the antiviral therapeutics market, making the market more competitive.
The late-stage pipeline drugs are expected to enter the market, positively impacting the market. Most antivirals are considered comparatively harmless to the host and therefore are used to treat infections. They are different from viricides, which are not used for medication but can destroy or deactivate virus particles outside or inside the body. Antiviral drugs are used in the treatment of patients suffering from herpes viruses, HIV, influenza A and B viruses, and hepatitis B and C viruses.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for antiviral drugs is projected to increase at a CAGR of 3.9% during the forecast period between 2023 and 2033, reaching a total of USD 89.68 billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3.8%.
During the historical outlook, the biggest driver of the overall antiviral drugs market was Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales, which accounted for more than half the share of the market in 2021. According to WHO, in 2021, several patients living with HIV are 38.4 million, and 650k people acquired the disease in the same year.
Nearly four out of five people were freshly put on treatment in sub-Saharan Africa. In 21 African countries with a high burden of HIV, two out of three people in need are receiving treatment, and two out of three positive pregnant women are receiving antiretroviral drugs to prevent HIV transmission to their infants.
The introduction of solid R&D activities, newer and advanced treatments, and formulations, such as vaccines and combination therapy, are projected to fuel the market growth of antiviral drugs over the forecast period.
The increasing commonness of viral infections such as HIV, Herpes, Influenza, and others is expected to upsurge the demand for antiviral medicines throughout the forecast period. For instance, according to UNAIDS, in 2020, more than 37 billion individuals were living with HIV across the globe.
Out of these, around 1.5 billion new people acquired HIV infection in 2020. Overall, the COVID-19 pandemic has pointedly accelerated the market growth in 2021, whereas a negative impact of the pandemic has been detected for other applications of antiviral drugs.
Owing to solid R&D activities, newer and advanced treatments, and formulations, such as vaccines, combination therapy, and others, are being introduced in the market, and the demand is anticipated to upsurge. Hence, strong R&D is one of the crucial factors in the antiviral drugs market growth.
Principal Consultant
Several factors hampering the market expansion of Antiviral Drugs include the high risk of failure, the high cost of R&D and therapy, and government austerity. However, the swelling usage of natural products and the high cost of developing drugs are the market's key challenges.
| Countries | Revenue Share % (2022) |
|---|---|
| United States | 7.1% |
| Germany | 5.8% |
| Japan | 6.4% |
| North America | 38.7% |
| Europe | 24.9% |
| Countries | CAGR % (2023 to 2033) |
|---|---|
| China | 4.7% |
| India | 3.8% |
| United Kingdom | 2.7% |
| Australia | 3.4% |
In terms of market contribution, North America acquired the leading share in revenue collection across the globe, accounting for a 38.7% share in 2022. As per the recent analysis by Future Market Insights, the region is anticipated to maintain its dominance during the assessment period 2022 to 2032. The United States and Canada are estimated to be the leading shareholders in regional revenue generation.
The market decline can be attributed to the loss of market exclusivity of patented drugs, mounting vaccination rates against viral infections, and government initiatives to minimize the prevalence of viral infections.
For instance, the United States government is responsible for several measures, including funding and grants in infectious diseases programs and encouraging the R&D activities of innovative therapies to manage viral infections.
Based on the geographies, European is the second-leading region, acquiring a 24.9% share in the antiviral drugs market. During the forecast period, the region is estimated to witness moderate growth, backed by soaring investments in the development of new drugs and therapies. This market growth is also attributed to the easy approval and promising healthcare policies by several governments.
In April 2022, European Medicines Agency, the European Union's drug regulator, signed off on emergency usage of Merck's Covid antiviral pill for adults who get tested positive as it prepares to decide on full approval by the year's end.
In July 2021, GSK and Vir announced a Joint Procurement Agreement (JPA) with the European Commission to supply up to 220,000 doses of sotrovimab. Following the grant of the marketing authorization in the EU, Member States participating in the JPA can now order sotrovimab to support their pandemic responses. These initiatives are likely to fuel the market growth of Antiviral Drugs in the coming years.
In the Asia Pacific, the market for antiviral drugs is anticipated to witness the fastest growth rate throughout the forecast period. The market's exponential growth can be attributed to the rising prevalence and treatment rate of viral infections, emerging healthcare infrastructure in the region, and growing awareness among people regarding infectious diseases.
Besides, the strong presence of generic pharmaceutical manufacturing companies in India, China, and other South Asian countries and the rising geriatric population in the region are some principal driving factors of the segment.
The introduction of new and innovative strategies in emerging economies is also likely to boost the demand for Antiviral Drugs over the coming decade.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Category | By Application Type |
|---|---|
| Leading Segment | HIV |
| Market Share (2022) | 44.0% |
| Category | By End Use |
|---|---|
| Leading Segment | Hospitals |
| Market Share (2022) | 47.80% |
The global antiviral drugs market is segmented based on product type and end user. The HIV segment captured the majority share in terms of market revenue generation and held the leading revenue share of 44.0% in 2022.
The segment is projected to observe the fastest growth rate over the forecast period. The rising prevalence of HIV infection associated with a high treatment rate, availability of branded drugs, and government initiatives to upsurge the treatment rate is projected to stimulate the market at a higher growth rate.
For instance, in 2019, the United States government introduced the Ending the HIV Epidemic (EHE) plan to end the HIV epidemic in the country by 2032. The initiative seeks to decrease HIV infections and enhance the diagnosis and treatment rate in the United States. Furthermore, the existence of strong pipeline drugs for HIV infection may also fuel market growth throughout the conjecture period.
The hepatitis segment held the second-leading revenue share in 2021. Escalating vaccination against hepatitis A and B is affecting the growth adversely. Besides, the COVID-19 pandemic has significantly augmented the growth of the other segment in 2020.
Recent Developments:
The market is valued at USD 61.42 billion in 2023.
AstraZeneca, Cipla, Bayer AG are the key market players.
The growth potential of the market is 3.9% through 2033.
The market is estimated to reach USD 89.68 billion by 2033.
The market registered a CAGR of 3.8% from 2018 to 2022.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type 5.1. Hepatitis-C Antivirals 5.2. HIV Antivirals 5.3. Herpes Antivirals 5.4. Hepatitis-B Antivirals 5.5. Influenza Antivirals 5.6. Others 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User 6.1. Hospitals 6.2. Clinics 6.3. Ambulatory Surgical Centers 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Western Europe 7.4. Eastern Europe 7.5. South Asia and Pacific 7.6. East Asia 7.7. Middle East and Africa 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. Roche 17.2. Gilead 17.3. GlaxoSmithKline 17.4. Bristol-Myers-Squibb 17.5. Abbott 17.6. AstraZeneca 17.7. Cipla 17.8. Bayer AG 17.9. Johnson & Johnson 17.10. Merck & Co 17.11. AbbVie 17.12. Aurobindo Pharma 17.13. Dr. Reddy’s Laboratories Ltd. 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Antiviral Drugs Market
